ProQR Therapeutics N.V. (PRQR) Financials

ProQR Therapeutics N.V. (PRQR) reported diluted earnings per share of -$0.47 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, ProQR Therapeutics N.V. (PRQR) had $108.5M in cash and equivalents against $0 in long-term debt.

ProQR Therapeutics N.V. (PRQR) has a return on equity of -85.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

ProQR Therapeutics N.V. (PRQR) recorded an outflow of $63.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

ProQR Therapeutics N.V. (PRQR) recorded an outflow of $62.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

ProQR Therapeutics N.V. (PRQR) had $132.3M in total assets as of fiscal year 2025, including both current and long-term assets.

ProQR Therapeutics N.V. (PRQR) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

ProQR Therapeutics N.V. (PRQR) invested $52.5M in research and development during fiscal year 2025.

ProQR Therapeutics N.V. (PRQR) had 105M shares outstanding as of fiscal year 2025.

ProQR Therapeutics N.V. (PRQR) had a current ratio of 3.09 as of fiscal year 2025, which is generally considered healthy.

ProQR Therapeutics N.V. (PRQR) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

ProQR Therapeutics N.V. (PRQR) had a liabilities-to-equity ratio of 1.28 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

ProQR Therapeutics N.V. (PRQR) had a return on assets of -37.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

ProQR Therapeutics N.V. (PRQR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $182.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

ProQR Therapeutics N.V. (PRQR) trades at 9.8x sales, its market capitalization divided by $18.7M revenue, FY2025. The market capitalization is $182.0M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

ProQR Therapeutics N.V. (PRQR) has an Altman Z-Score of -4.75, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

ProQR Therapeutics N.V. (PRQR) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

ProQR Therapeutics N.V. (PRQR) reported a net loss of $49.5M while operations used $62.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

ProQR Therapeutics N.V. (PRQR) reported an operating loss of $51.0M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.